Shattuck Labs (STTK) Set to Release Earnings on Tuesday

Shattuck Labs (NASDAQ:STTK) will likely be announcing its Q3 2026 resultson Tuesday, November 10th. Analysts expect Shattuck Labs to announce earnings of ($0.10) per share and revenue of $0.03 million for the quarter. Parties can find conference call details on the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Friday, November 13, 2026 at 12:30 PM ET.

Shattuck Labs (NASDAQ:STTK) last posted its quarterly earnings data on Tuesday, August 11th. The company reported ($0.12) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.12). On average, analysts expect Shattuck Labs to post ($0.45) EPS for the current fiscal year and ($0.49) EPS for the next fiscal year.

Shattuck Labs Stock Up 2.0%

Shares of STTK stock traded up $0.10 during trading on Tuesday, reaching $5.42. The company’s stock had a trading volume of 61,072 shares, compared to its average volume of 965,515. The business has a fifty day moving average price of $6.24 and a 200-day moving average price of $6.02. The company has a market cap of $544.47 million, a price-to-earnings ratio of -10.64 and a beta of 1.09. Shattuck Labs has a one year low of $1.72 and a one year high of $8.33.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on STTK. Wedbush raised their target price on shares of Shattuck Labs from $11.00 to $14.00 and gave the company an “outperform” rating in a research report on Friday, October 2nd. Weiss Ratings restated a “sell (d-)” rating on shares of Shattuck Labs in a research note on Friday, September 11th. Leerink Partners assumed coverage on shares of Shattuck Labs in a research note on Monday, July 20th. They set an “outperform” rating and a $16.00 price objective for the company. UBS Group assumed coverage on Shattuck Labs in a report on Sunday, October 11th. They issued a “buy” rating and a $17.00 price objective for the company. Finally, HC Wainwright lowered their target price on Shattuck Labs from $18.00 to $14.00 and set a “buy” rating on the stock in a research report on Tuesday, August 11th. Three research analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average target price of $13.70.

Shattuck Labs Company Profile

Shattuck Labs, Inc is a clinical-stage biotechnology company focused on developing novel immunotherapies for the treatment of cancer. The company’s research is based on its Agonist Redirected Checkpoint (ARC) platform, which is designed to combine immune-cell activation with checkpoint inhibition in a single therapeutic molecule.

Shattuck’s pipeline has included bifunctional fusion proteins such as SL-172154, an investigational therapy designed to engage CD40 ligand and block PD-L1, and SL-173154, which is designed to target CD27 ligand and PD-L1.